2006
DOI: 10.1016/s0022-5347(05)01045-1
|View full text |Cite
|
Sign up to set email alerts
|

A Phase II Trial of TIP (Paclitaxel, Ifosfamide and Cisplatin) Given as Second-Line (Post-BEP) Salvage Chemotherapy for Patients With Metastatic Germ Cell Cancer: A Medical Research Council Trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
34
0

Year Published

2007
2007
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 23 publications
(37 citation statements)
references
References 0 publications
3
34
0
Order By: Relevance
“…170,171,173,[175][176][177][178][179] With these regimens, long-term disease control can be achieved in between 15% to 60% of patients. Given that no randomized trials exist comparing these chemotherapy combinations, no recommendation can be made as to which regimen is superior or should be used as the standard management.…”
Section: Standard Dose Chemotherapymentioning
confidence: 99%
“…170,171,173,[175][176][177][178][179] With these regimens, long-term disease control can be achieved in between 15% to 60% of patients. Given that no randomized trials exist comparing these chemotherapy combinations, no recommendation can be made as to which regimen is superior or should be used as the standard management.…”
Section: Standard Dose Chemotherapymentioning
confidence: 99%
“…The mainstay TGCT treatment over the last decades has been platinum-based chemotherapy associated with surgery, leading to high response rates and also in some cases to a curable disease [11]. Nevertheless, the development of refractory disease is still a challenge in around 15 % of the cases, and even within this group, there is a large range of risk [12,13]. Currently, the risk stratification of the patients is based only on clinical parameters as the spreading pattern and serum levels of human chorionic gonadotropin (hCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH).…”
Section: Introductionmentioning
confidence: 99%
“…[7][8][9][10] Paclitaxelcontaining therapy, such as TIP therapy, has shown a particularly good response rate and longer survival in first relapses of GCT. 11,12 The National Comprehensive Cancer Network guideline recommends TIP therapy as a second-line chemotherapy in cases with good prognostic features. 13 However, in cases with poor prognostic features, such as cisplatin resistance or multiple relapses after cisplatin-based chemotherapy, the prognosis has remained poor.…”
Section: Introductionmentioning
confidence: 99%